In patients age younger than 60 years, ibrutinib plus R-CHOP in untreated non-GCB DLBCL improved event-free survival, PFS, and OS with manageable safety and can significantly improve untreated non-GCB DLBCL co-expressing BCL2 and MYC genes [30, 31]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.